Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.
about
Human exonuclease I is required for 5' and 3' mismatch repairMutS homologue hMSH5: role in cisplatin-induced DNA damage responseDNA polymerase delta is required for human mismatch repair in vitroInteraction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatinMechanisms of resistance to alkylating agentsMSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instabilitySystems biology of cisplatin resistance: past, present and futureFlanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-LinksFunctional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLalpha.Chemoresistance and targeted therapies in ovarian and endometrial cancersAdenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling?DNA mismatch repair in eukaryotes and bacteriaDifferent mutator phenotypes in Mlh1- versus Pms2-deficient miceMismatch repair and treatment resistance in ovarian cancer.Functions of MutLalpha, replication protein A (RPA), and HMGB1 in 5'-directed mismatch repairHuman MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells.Construction and characterization of mismatch-containing circular DNA molecules competent for assessment of nick-directed human mismatch repair in vitro.The role of mismatch repair in the prevention of base pair mutations in Saccharomyces cerevisiae.A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype.Hydrolytic function of Exo1 in mammalian mismatch repair.Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injectionDeficiency of a novel mismatch repair activity in a bladder tumor cell line.Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancerSilencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1Mismatch repair processing of carcinogen-DNA adducts triggers apoptosisMismatch repair in correction of replication errors and processing of DNA damage.Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancerDNA damage during reoxygenation elicits a Chk2-dependent checkpoint responseCurcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathwaysSelective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.Malaria drug resistance is associated with defective DNA mismatch repair.The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations.Genetic instability and transitional cell carcinoma of the bladder.Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.Cisplatin damage: are DNA repair proteins saviors or traitors to the cell?Molecular testing for microsatellite instability and its value in tumor characterization.Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.Nucleotide excision repair and anti-cancer chemotherapy
P2860
Q24292224-F9C7E18C-4398-44E0-8DA5-E2F4351C7A0FQ24306821-AC124499-3FA8-49E9-9FA5-5D1E384912CCQ24313002-087764F3-5320-4F61-8EDB-E4873F513116Q24553992-C60AF9F8-9C88-47B9-9758-2917C5542103Q24596948-630F21A3-A1C2-444C-99A7-4961F1D929FEQ24810372-158A0435-320A-43ED-BCD5-12572723FDFAQ26863585-671762CC-B5DE-40C4-B535-6EEDDE77DF6DQ27671829-089C97C4-B433-4908-86BC-0BA3942650F3Q27929951-65EE1472-4FA3-4A70-809C-6B912E82698EQ28073246-969E669C-120A-4D3A-A172-405C5F3DC9A3Q28212223-B9C909CD-A184-47A3-868A-8DCCB93EEA77Q28237728-C1472F6C-4D6E-45EB-AE02-C1457304D974Q28291067-F60ADCB3-3EFC-40D2-A8E7-9A67F9997AEAQ28592891-200B372B-BB6D-4F05-B99C-B30291CBBECCQ33252378-A2FCE4A0-427D-41E5-94DB-6D880F59D631Q33465403-1863BA4D-8997-459C-8A06-F8D277A4A4B1Q33554104-EF61585D-FB8C-4DCA-9F6B-C67403E13156Q33559854-79F2BBD2-70AB-4F50-8B55-1468BBA0C58CQ33592366-1EE76901-4E26-473B-943B-8249ADDB17F0Q33772742-DA037212-72B1-4A38-847D-32CA447421E3Q33791326-B4F78975-D302-46C9-869F-1ADE677306B5Q33821563-D808C1C8-6D94-4248-A595-704A28F2D1BCQ33888905-CB91F38C-5C98-4111-9484-21EF4A047D12Q33919232-3BFCDC6D-42B5-40C9-82A2-197B1F393C1DQ33954219-39D56D8E-5609-4162-A6DE-DF94A5F73EDDQ33960642-8B0E79F7-EFB1-4037-9EBF-5D19FC7B99B5Q34194518-EC3E2334-8C32-468C-80B7-CC6456906F83Q34433775-F75662D1-6B30-43FC-9A8E-D21F6BAC94E7Q34519722-466A5E0F-9E02-4E63-A46C-DF83B36CF542Q34603280-7E88A387-925A-4847-A0E6-697234AA0FE6Q34625095-9F070F1A-6F31-4033-9D38-25541788F4FDQ34625375-60293546-0207-44A4-BC72-82B63B18C888Q34785704-DA15E9FE-16CA-496F-9C25-F89CE1011280Q34786141-FAA61694-5198-4E81-9DAA-5C8E092FA62AQ35608919-C59AE4FC-947B-43A7-9453-E7B5A6DAFF20Q35663759-B0923128-873D-4968-A859-9547F611FD44Q36149816-80E1006B-1982-42D2-A080-ADC41B39F710Q36192733-8079489A-B8E4-4503-B4D3-3DA20AD79A4AQ36213486-73875EF0-1436-43D3-9C84-E39907C45063Q36254803-4757D93E-BE67-4206-9791-B17ED3E01106
P2860
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cisplatin and adriamycin resis ...... in an ovarian tumor cell line.
@en
type
label
Cisplatin and adriamycin resis ...... in an ovarian tumor cell line.
@en
prefLabel
Cisplatin and adriamycin resis ...... in an ovarian tumor cell line.
@en
P2093
P2860
P356
P1476
Cisplatin and adriamycin resis ...... in an ovarian tumor cell line.
@en
P2093
P2860
P304
19645-19648
P356
10.1074/JBC.271.33.19645
P407
P577
1996-08-01T00:00:00Z